Vigil Neuroscience Advances Alzheimer’s Trial, Eyes 2025 Data
Company Announcements

Vigil Neuroscience Advances Alzheimer’s Trial, Eyes 2025 Data

The latest update is out from Vigil Neuroscience Inc ( (VIGL) ).

Vigil Neuroscience, Inc. has announced the FDA’s removal of the partial clinical hold on its Phase 1 trial of VG-3927, potentially advancing Alzheimer’s treatment. The company’s interim data suggests safety, tolerability, and once-daily dosing of VG-3927, alongside positive biomarker responses. This regulatory milestone enables further exploration of VG-3927’s full pharmacology, with complete Phase 1 data expected in early 2025, marking a significant step in the development of novel therapies for neurodegenerative diseases.

For an in-depth examination of VIGL stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskVigil Neuroscience Advances Key Clinical Programs
TheFlyVigil Neuroscience reports Q3 EPS (47c), consensus (54c)
TheFlyVigil Neuroscience story ‘gaining momentum,’ says Jefferies
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App